Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

Loading news article.

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration | WAPE

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

Article summary

Related companies

Comments —